||5R01CA238087-04 Interpret this number
||Cleveland Clinic Lerner Com-Cwru
||Biological Determinants of Colorectal Cancer Outcomes in Latinos of Diverseýancestral Origins
Hispanics/Latinos (Latinos) are the 2nd largest and fastest growing ethnic group in the United States. Although
typically grouped as a single ethnic minority, Latinos are a heterogeneous population with diverse national
origins, unique genetic admixture patterns (African, European, and Indigenous American ancestry), and a wide
spectrum of socio-demographic characteristics. Colorectal cancer (CRC) is the second most common and fatal
cancer among all Latinos combined; however, mortality rates differ substantially within Latino subpopulations
defined, thus far, by place of birth. Rates are substantially higher in Puerto Ricans and Cubans, the subgroups
with the highest African ancestry, than in Mexicans and non-Hispanic Whites (NHW). After accounting for
socioeconomic status and access to care inequalities, differences in mortality persist, highlighting the need to
accurately characterize and critically assess biological contributors to intra- and inter-ethnic group disparities.
To overcome Latino underrepresentation in publicly available datasets, we propose to join resources from well-
annotated epidemiologic studies including the Hispanic Colorectal Cancer Study (HCCS, R01CA155101), the
Puerto Rico Biobank (PRBB, U54CA163068), and the Moffitt Cancer Center Total Cancer Care (TCC) cohort
into a new consortium, the Latino Colorectal Cancer Consortium (LC3). This strategy allows us to maximize
sample size and adequately represent the most common Latino subgroups in the US (i.e. Mexican, with high
Indigenous American ancestry; Puerto Rican; and Cuban). We will characterize the somatic mutational profiles
of Latino CRCs by whole exome sequencing using previously-collected tissues from the HCCS, PRBB, and
TCC (n=600). For comparisons across racial/ethnic groups, we will leverage existing tumor sequencing data
from NHW and African American (AA) CRCs in the Genetics and Epidemiology of Colorectal Cancer
Consortium (GECCO; 7,000 NHW), The Cancer Genome Atlas (283 NHW and 61 AA), and TCC (589 NHW
and 40 AA). Here, we will examine driver mutation frequencies associated with estimated local and global
genetic ancestry in Latino CRC cases (Aim 1), conduct a trans-ethnic analysis comparing frequencies of
ancestry-associated and known clinically-actionable driver mutations in Latinos to NHW and AA (Aim 2), and
assess the implications of genetic ancestry for survival as well as differential efficacy of conventional and
potential targeted therapies for metastatic CRC using patient-derived xenograft (PDX)-based ex vivo live tissue
sensitivity assays (LTSA) (Aim 3). Ancestry-specific PDX models will be established using fresh tissue from 40
prospectively recruited Latino, AA, and NHW TCC participants. Our innovative LTSA approach permits timely
screening of multiple therapeutic agents while maintaining the tumor microenvironment and reliably predicting
clinical responses. Results from this study will help us better understand the biological underpinnings of
outcome disparities in Latino subgroups to inform translational efforts towards precision clinical applications.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.